Mosaic-8 RBD-nanoparticles show promise against current and future SARS-CoV-2 variants
| Date | 30th, Jun 2022 |
|---|---|
| Source | News Medical - Scientific News Websites |
DESCRIPTION
A recent study posted to the bioRxiv* preprint server supports using mosaic sarbecovirus receptor-binding domain (RBD)-nanoparticles to discover therapeutic pan-variant and pan-sarbecovirus monoclonal antibodies (mAbs) and to induce mAbs by vaccination.